Clinical Trials Logo

Seizures, Epileptic clinical trials

View clinical trials related to Seizures, Epileptic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05518578 Recruiting - Epilepsy Clinical Trials

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

NCT ID: NCT04076449 Recruiting - Epilepsy Clinical Trials

Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

CRESS
Start date: September 3, 2019
Phase:
Study type: Observational

Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.

NCT ID: NCT02424123 Completed - Epilepsy Clinical Trials

Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults?

SeizS100B
Start date: October 11, 2016
Phase:
Study type: Observational

Seizures represent an important clinical problem, accounting for at least 40% of adult onset epilepsy. Predicting seizure recurrence in subjects experiencing a first seizure is difficult due to the lack of prognostic biomarkers. Recent evidence has indicated that blood-brain barrier (BBB) dysfunction constitutes an etiological factor to seizures. In particular, it has been shown that modification of BBB permeability is associated with seizure activity. In addition, it was demonstrated that BBB permeability can be assessed by measuring serum level of the protein S100B. Based on these data and considerations the investigators will test whether the extent of BBB damage at time of first seizure is predictive for seizure recurrence. The main objective of this study is to evaluate the association between the absolute (ng/ml) serum S100B levels (measured at time of the first seizure) and the experience, or not, of seizure recurrence within one year of follow-up.

NCT ID: NCT00297323 Completed - Seizures, Epileptic Clinical Trials

An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy

Start date: June 2005
Phase: N/A
Study type: Observational

The purpose of this observational study is to evaluate the safety of topiramate in adults and children with epilepsy (or seizures) who have not received or have not responded to treatment with previous antiepileptic medication.